Merck & Co. Pushes Back On Modest Projections For Verquvo

 
• By Joseph Haas

Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.

broken paper red heart isolated on pink background, top view, flat lay
Vericiguat approval brings a novel mechanism of action to HFrEF patients

More from New Products

More from Scrip